NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$121.19 +2.20 (+1.85 %)
(As of 06/22/2018 12:49 PM ET)
Previous Close$119.12
Today's Range$118.38 - $121.19
52-Week Range$33.15 - $122.43
Volume1,287 shs
Average Volume227,721 shs
Market Capitalization$2.22 billion
P/E Ratio130.76
Dividend YieldN/A
Beta1.07
Enanta Pharmaceuticals logoEnanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Debt-to-Equity RatioN/A
Current Ratio17.86
Quick Ratio17.86

Price-To-Earnings

Trailing P/E Ratio130.76
Forward P/E Ratio36.07
P/E GrowthN/A

Sales & Book Value

Annual Sales$102.81 million
Price / Sales22.72
Cash Flow$1.1308 per share
Price / Cash107.17
Book Value$15.80 per share
Price / Book7.67

Profitability

EPS (Most Recent Fiscal Year)$0.91
Net Income$17.71 million
Net Margins31.60%
Return on Equity18.50%
Return on Assets17.30%

Miscellaneous

Employees89
Outstanding Shares19,270,000

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported $0.61 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.53 by $0.08. The biotechnology company had revenue of $44 million for the quarter, compared to the consensus estimate of $40.77 million. Enanta Pharmaceuticals had a return on equity of 18.50% and a net margin of 31.60%. The company's revenue was up 388.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.28) EPS. View Enanta Pharmaceuticals' Earnings History.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Enanta Pharmaceuticals.

What price target have analysts set for ENTA?

6 equities research analysts have issued 1-year price objectives for Enanta Pharmaceuticals' shares. Their forecasts range from $36.00 to $135.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $79.1667 in the next twelve months. View Analyst Ratings for Enanta Pharmaceuticals.

Who are some of Enanta Pharmaceuticals' key competitors?

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 62)
  • Mr. Paul J. Mellett Jr., Sr. VP-Fin. & Admin., CFO and Principal Accounting Officer (Age 63)
  • Dr. Yat Sun Or, Sr. VP-R&D and Chief Scientific Officer (Age 66)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 52)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 64)

Has Enanta Pharmaceuticals been receiving favorable news coverage?

Press coverage about ENTA stock has been trending somewhat positive on Friday, Accern reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enanta Pharmaceuticals earned a news sentiment score of 0.04 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.99 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.34%), Farallon Capital Management LLC (4.75%), Dimensional Fund Advisors LP (3.10%), Franklin Resources Inc. (1.49%), Matarin Capital Management LLC (1.17%) and Prudential Financial Inc. (1.13%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Which institutional investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Franklin Resources Inc., Barclays PLC, Virginia Retirement Systems ET AL, Farallon Capital Management LLC and Northern Trust Corp. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda and Paul J Mellett. View Insider Buying and Selling for Enanta Pharmaceuticals.

Which institutional investors are buying Enanta Pharmaceuticals stock?

ENTA stock was purchased by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Prudential Financial Inc., Spark Investment Management LLC, California Public Employees Retirement System, Dimensional Fund Advisors LP, Chicago Equity Partners LLC, UBS Group AG and Russell Investments Group Ltd.. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $121.19.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $2.22 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (ENTA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  184 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  378
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.